Search Results - "da Silva, Rafael Lopes Paixão"
-
1
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
Published in Communications medicine (15-11-2021)“…Background The SARS-CoV-2 variant of concern (VOC) P.1 (Gamma variant) emerged in the Amazonas State, Brazil, in November 2020. The epidemiological…”
Get full text
Journal Article -
2
Brazil in the face of new SARS-CoV-2 variants: emergencies and challenges in public health
Published in Revista brasileira de epidemiologia (2021)“…This article discusses the epidemic situation of Covid-19 in Brazil, in the face of the emergence of a new strain called P.1, which is more transmissible and…”
Get full text
Journal Article -
3
Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2
Published in PLoS computational biology (01-03-2022)“…The SARS-CoV-2 pandemic is a major concern all over the world and, as vaccines became available at the end of 2020, optimal vaccination strategies were…”
Get full text
Journal Article -
4
Area-level inequalities in Covid-19 outcomes in Brazil in 2020 and 2021: An analysis of 1,894,165 severe Covid-19 cases
Published in Preventive medicine (01-11-2022)“…The study aims to analyze inequalities in Covid-19 outcomes in Brazil in 2020/2021 according to the per capita Gross Domestic Product (pcGDP) of…”
Get full text
Journal Article -
5
Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis
Published in Lancet Regional Health - Americas (Online) (01-01-2023)“…Vaccines developed between 2020 and 2021 against the SARS-CoV-2 virus were designed to diminish the severity and prevent deaths due to COVID-19. However,…”
Get full text
Journal Article -
6
Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysisResearch in context
Published in Lancet Regional Health - Americas (Online) (01-01-2023)“…Background: Vaccines developed between 2020 and 2021 against the SARS-CoV-2 virus were designed to diminish the severity and prevent deaths due to COVID-19…”
Get full text
Journal Article